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: Data ali rloli mailabie iPorn rbme huge-scale. wn&oml2ed 
this that dimtly comk the risks and benefits of thromClyti~ 
agents la mite ruipmdlal iafsrttian. In the int&pretktion of 
resnl~ from the Gmppa ~taliano per lo St&o delii Soprawi- 
vema neB%&to Miocmdieo (GISSI-2) trial and its Ilnkr~a~- 
tisnal Extensioa, &e Third kt&atio~ Study of Enlilrct SW- 
vivd (Is153), &lid the’Global Util~on of §treptokln8se and 
Tkiue Plasmin*, Activa*r for -O&tded Com~ary Arteries 
(GIJSTU-I) trial, there are areas of boih agreement and contra-: 
.~ItiS.~~~~tllatthe~bmost~~mon~ygused 
iu the U&MI SWes-tlsSue-type piasminogen activator (t-PA), 
streptoktuase and a@oylated plasminog~~ strept&ie?se activa- 
tar eoz~plex (@SAC)+IH ~&t&e mortality when giver to pa. 
tlents v&b acute evoking .myocarrfial in~tittn. Further,, it ,is 
c&m @mt tlmmb~~tk therapy given to stich patients presenting, 
Despite clear evit+we of net ,benefit For all the -widely used 
thrombofytic agents, there is controversy about whether any 
particrd~r drug has an optimal benefit&k ratio (l-3). .We here 
review the Second Gruppo Italian0 per to Studio della Soprov- 
vi-ma nell’infarto Miocardico (%ISSI-2) trial (4) ,;artd its 
Internatioitat Study Group (S), the Third Intemationtil Study 
ofizifam Sun&i (ISIS-3) (6);a@the,Pii? Gloha~ Utiljzation. 
of Streptokinase ‘and T~stie ~~kminogen Activator for: Oc- 
eluded Cotinary Arteries (GUSTO-I). (7). trials to provide a 
ratiopal basis for bealth:providers as well a:, policy ma!;& to 
make-the best decisions for treatment of patients with acute 




up to: 12 b-d& onset &f symptotis reducei the ind&Mty rate by, 
-2096, that aspirbi tbtipy fdr p&.ients present&kg up ti‘24 b’. 
reduces tbe morta!ity r&e by -23% and that the beadts of 
thrombo@tic therapy and aspirin are additive. lklly, and of 
most hnpurtaaee, the earlier ad&r&ration as well as tbe’nkre 
tidespread use of tbrombolytic therapy itnd aspirin w&d save 
many more liven The totality of evidence clearly indicates that 
streptoldnase produd signigcantly f&ver strokes &d eerebr@ 
heniorrha@ than either t-PA ,or APSAC. Wh&er or not .accel- 
erated t-PA has a small. orbvan(age for mortality is less conclusive. 
Ai present, any smafl differences in safely, eikacy and ease of 
administration of di&reat tbrornbolytic agents a* far onti&bed 
&y the large heneffts that would accnre firm earlier administra- 
tion and wider utilization of any of these drugs. 
u Am cd cnrdid 19~~~22~) 
Data Fmm Thnmbqlytk Comparisons in 
G%SW2, ISIS-3 and GUSTB-1 
In GISSI-2 and its international Study Group Fstension. 
20,891 patients were randomized within 6 h of onset of 
symptoms of acute myocardial infarction to reccitie strepoki- 
nase: or. tissue-type : piasmitiogen a&iv&or &PA, [aiteplase]) 
(4,5), both administered. in, the conventional. tiannef. ,Tfie 
administration of-3.00 to 325 mg of-a@rin daily w& retin;- 
mended, and sIl patients were further randomized to rece& 
ejtiler subcuianoous heparin (12,500 IW twice daily) beginning 
12 h after &ntiomiz&on or a no-heparin control therapy. The 
GISSI-2 trial showed’no digerenw in morta&y rate for t-PA 
versus~streptokin& but a significant e%cess of stroki for t-PA 
of -4 per l$Otj fp = 0.008) atid an apparent’.ezcess tif cerebral 
hemorrhage for t-PA. of ~1.3 per, 1,000, which wa& ‘not 
signiikr+nt ,(p = ‘0.10) <Table I). ,, ‘, ‘: ‘I 
In ISIS-3, .41,299 pstients were rando+zedd: within 24 h to 
receive streptokinase, anisoylated plasmino@~ streptokicinase 
activator ~eomplex~(APSAC!) or t-P~$h&plas& all adminis- 
tered in tlie conveutio$at manner (6). Au patients rec&ed 
MZrng of aspirin daiIy ,for 30 days arid weft further random-~ 
ized to’ receive’either subctitaneous heparin (.1,2,5ilO IU twice 
daily) beginning’ 4. -h -after: randomization or -a no-heparin 
contkoi therapy. As in GISSf-2,151S~3 showed no dierence in 
mortality rate for t-PA versus streptokinase but a signiftcantly 
higher rate of total stroke foe t-PA of -4,per l,NtO (2p < 0.01)’ 
SK+ scIicparin 
t-PA + IV heparin 
SK + IV hcparin 
t-PA + SK + IV heparin 
1 
7.2 : 1.22 0.49 
6.3 1.55 0.72 
7.4 1.4 0.54 
7.0 1.64 0.94 
SEptokinase {SK) (1.5 million U OCR 30 :o 6tJ min) and tissue-type 
plasminogen activator (t-PA) (100 mg over 3 h = IO-mg bolus + 50 mg in first 
hour + 40 mg in next 2 h) in GISSI+$ streptokinase (1.5 miilion U over 60 min), 
anisoy!ated plasminogen’sireptokinase activato!~complex (APSAC) (Xi U over 
3 min) a!d t-PA (0.6 million U&g over 4 h = O&i-million U/kg bolus + 036 
m%liqn U/kg in first hour + 0.2 million U/kg in ve$3 h) in ISIS-3, streptokinasc 
(1.5 million U over 60 thin), t-PA (1On mg over 1.5 h = 15mg bolus t 
475 m&g body weight irrneti 30 min + 0.5 mg/kg in next 1 h) or combination 
of t-PA (1.0 mg&g in first hour v&h I@% given’& holus) and streptdkimuz (I.0 
miIlion IJ in tit hour) in GUSH&I. IV = intrayenoltri; SC = subcutaneous. 
as well & an excess of ckiebral herriorrhagi: for i-PA of 4 per 
1,000, which was significant (2p < MIONI). The ISJS-3 trial 
sbowecl no difference in mortality iate for AlSAC but, as for 
t-PA, somewhat higher rates of intracerebral hemorrhage and 
stroke compared with those for s?reptokina!e @able 1). 
Both GISSL2 and ISIS-3 compared similar conventiona 
regimens of MA and streptokinase in the presence 01 ade- 
+iate asfiirin and randomized patients to receive an antithrom- 
botii: regimln of deliyed subcutti~~eous heparin; An overv&, 
‘oi meta-analysis,’ of,.the t&o. ttials- yields. i&ntieal m&My 
rates for !-PA versus strept&inase. Specific&y, there wafi .a. 
1 SD difference against t-PA (a!t@ase) in GISSI-2 and a 1 SD 
diBeFnc&in,favor of t-PA (dutep1as.z) in ISIS-3, so that.ovetill! 
2,411 (10.0%) Of 24,118 @i&s treated witlr t-PA and 2;413 
~(10.0%) of 24,176 patients treaded with streptokinti died;‘As 
‘c&e wouldiqxpect froti the re&lts of,the. individual t&Is, in 
&is meta-analysis, there ‘was a. sign&ant ‘excess of strokk foi 
t-PA of4 per ~1,000 (2p < S,w!) as W&t1 asa ~igr++t excess 
,of cerehrai -hem&&age fGr t-PA of, 7-3 ‘per, 1,ooO (2p -C 
0.00001) (6). ; ” i : 
!n’GU~TO-1;. 4i,O21 patie& weti randomized vjithin 6 h 
to four differ+ treatment &I& and al! p&etiti received an. 
i~$ti&dos& of 160 mg’bf oral aspirin +d-3ti&g.daiiy tti&after 
(7)* The randomized arms included hvo new tieans tq admin- 
ister t-PA (&plF),. $ne using an a~lerated~regimen’ plus 
immediate intiveni~us heparin (n = 10,396) and the second a 
pm-tidy a&&rated regiinei~ comb&I &!I stieptokinase tid 
tiediate intravenous heparin (n ,=; 1OJ74). The other two 
arms both utilized cowentiond strmlokina6e~ either with 
.~. 




immediate in~r&~~~oti. hcpahn. @I = 10,4K9, which had ntii 
ken .tested pr&iously ii~ a, large-scale’ tidal, ore with ‘delayed 
subcutaneouS hep&n (n Y ~9&$1). This latter arm was identi- 
cai to: t’he’ regimen used in. KXS-3 and corn&able to that used 
in GISSI-2. The GUSTO investigators &&d that’this arm was 
added after the start of the &at on the basis .of the results of 
ISi5-3 and GISSI-2, & ,& “to provide ‘an Mheniiq and 
contemporary reference with which rhe o;i:~r three experiment, 
@I iums Can be comp&ed in order to app&b$L?:ly test the 
probability of lower mortality withotit an undue incretit ir the 
risk of intracerebral hemorrhage” (8). However, in CUSW-1 
there *as no comparison of iqtravefious versus subutzineous 
heparin iti patients-assigried to receiie ac&letited l&PA: a& 
APSAC was not tested. Because rione of the three crrperimen? 
taI,arms had been tested previously, none had been approved 
by the U.S. Food and Drug Administration. 
The prim&-y diriicai findings of the GUSTO-I, trial were 
that 1) stieptokinase plus immediate intravenous heparin had 
no advarltzge in terms of either mortality .rate or a combined 
cild point of moitality and nonfat&l stroke rat& compared with’ 
that for streptqkicase plus delayed subcutaneous ‘hebarin; 
2) accelerated-dose t-PA combined with streptokinase and 
immediate intravenous hepaiin had no beneficial effect foi 
these end points compared with that for stre@okinase plus 
.delayed subcutaneous heparin; and 3) accelerateddose t-PA 
plus immediate intravenousheparin had a small but significarit 
decreaie c;f 9 per 1,000 in’morta!ity and a 7. per t;C@O decrease 
in ttie pies;wified comb&d C&&XI end point uf death pius 
nonf$a! stroke, of bor&.:line significance. As in GE&Z and 
ISIS-.3, GWSf&l showed,. a sign&ant excess of stroke fur 
ace Aerated t-PA of -33 per l,(wo (p’< 0.05) and a significant 
excess of cerebral hemorrhage of 2.3 per 1,000’ (p c 0.03) 
compared with that for streptokinase grid delayed Cubcuiane- 
ous heparin. 
Publication of the GUSTO-l. re~lts has stimdatccj much 
discussion ‘and, debate @bout ~thrombolytic theraby in acute 
myo&diaI infarction (l-3,9-14). Some of ‘the controvey 
conbems the prqer. interpretation of the ,magnide of differ.- 
ences between agea&- the potentiti! iinpact of an @XI-label 
design and .the meaning of. o+etied effects ‘iti pF@fied 
SUbgpiIps. 
With rtigarh to ~tbe magnit& -tif di&r&ces betwe& 
agents, &q~rison of the ac+@ated.i t-PA. ati ,@th the 
stcep~okin~;plus sut@an~~ hepariti arm’in.the GU!YI’&! 
data yields a s&II di&reice in m&-taIiG rate in fatiur of $-PA 
tioi seen in GE&2 br IS&*3 but an increase in stroke and 
cerebral hemprrhige agitist :“pA. sin+. to thgt found in 
j ~Iss’I-2~+1d IS&3. However, in,th,s report of the CWXO-1 
trial both’the stre$tokinzz arm ,ti# imWdiate imra~sous 
‘hep arin aysd the strep~okinaskz arm wi&&!ayed subcutaneous 
werecombined. As one wtiu err0ect; 
,- . . . :, .: ,< .; 
ison yields a som&hat IPGH pad moth s&$&tit diffkrence ir: 
mortatity ‘of 10 .per. @DO in iavo; of t-PA’ cp 7 O.&], a 
wnsignmt di&rence in stroke of.:2 per i,DDD agfnst t-PA 
ip = 0.09) and a swcant excess in hemo~agi~ &tke of 
2 per t,WO against t-PA (p = ,O.O+ Thus, such a,coqxu%n: 
increases ihe di&rence iti mortality .in favqr of t-PA’ and 
decreae+e diiferencz in stroke against t-PA.. : ” 
FM&$, the G@TU-1 i&@iga’fors recogntied- the impor- 
tance of a priori prespeci&d analyses qf ctinically relevant 
outcomes ‘to avoid the bias inherent in a -posteriori data- 
derived comparisons. In fact, usirig the pr&pectivelj defined 
&jar end poitit for net din&I benefit of de& plus, nonfatal 
stroke (3,15), our. caI&ated’ p value. was of bgrcleriine, statis- 
tical signi- (p = U.D6), and @e OubIished ripor: (7) 
ptients death plus diwbling stroke, a comparison thst is 
st&i&alIy signi@ant at p = 0.03. 
‘4 second: area of &ntrover@ sutiounds the potential 
&pact ,of an open-label design. Although all patients in 
GUSTO-1 were randomized, therapies were nut double bfind, 
so the investigators, treding clinjcians as well as patients were 
aware of, which therapr was .given. A major strengtil ‘of 
stion is to yield, on average, the equal distribution 
among zriaf &ms of b@ine facto& at the time of randomha: 
t&m (&$ as &e, type of myocardial infarction or time to 
tp+tnent). that @d conftiuad .obs&ed associations between 
treatiuent &d outcome:(l5). As expected, because of the large 
sample size, ra+tiization in GUST0-1 achieved a similarity 
of all baseline variables for ,ali four. arms. However, because of 
&e o$en-Iabel design, it is possible that Hesaving interventions 
used~after the time of &ndomi&ion may inadvertently have 
been &en more in 06 arm .than another, thus confounding 
the obser&d @tsociation between treatment ,and outcome (15:. 
b GUSTU-I, the:nontrial ititerventions’that may lWe been 
di&entiaIIy utilized and th&. also have cIear mortality- 
reducing ,effe&ts include beta+drenergic blocking agents, an- 
giotens&onveging -.eme inhibitors, acute -percutaneous 
tramI*+ dorunary angidglpty and ,+onz@ artery byPass 
grafting. Analyses +djusting for rhe use of $tibK i$ervention$ 
.are p+rti+l&y imp@ant in unblinded trials j as well as when’ 
di&renc& ia? efficacy between regimens are smaII, as in 
GUST+11 IXff&ential.utiIizati~n,of such lifesaving therapies 
might plausib~’ d&in&h of ev& et+n$ate the ,statistical 
sign&v 6f the ~&port& SW di&ei.rces i,b efficacy: In thiS 
regard, initial disizussion: (1’,3,16) of the GU$‘T0-1 final. data 
&&ated f&at b-s graft rates were 9.5% in the’accelerated 
t-PA arm aad. 8.5% @the streptokinase m, combined, bit in 
SubseqznePt pUbti~0nS (2,171, the magnit$e of this diff& 
enlce now appears to be somewhat ie& (9.0% for t-PA vs. 8.3%. 
fmzsmqto~). 
A third area of controv@sy &rounds the, prop& ‘i&pr& 
. ..- ,’ 
..:, ‘<:. 
., 
:, : +X vol. 8, No:7 l:~..+pIeni&t) 
:’ >unc 199” ‘8s -22s :::‘. . ..’ .,. -..,. :. ..,i : ..-. 
b&use ofthe jkgtotial @k ;Of bi&. Th&‘GW$l&i ;nvc&-: 
ton recognized this in their descripiion of selecied,gredeii&i 
.stibgroup a&$&es-time .tO .treatmen& infarct Ic~stion~,a@d 
agel-identi$ ; to th+e aat have. b&en &ICustirrely :in+esti-, 
gat+I in’ other; trials as, welt as’iri a rticcntly lx&h&d qxnpre- ., 
hensive ov&v& or mct&nalysis (18). :’ 
: ,Tn ooe of the moot i*p+nt of th&-se pres+fied an&es,‘, 
the GUSTO-C jfina! report stated @at -an interactioq between 
drug and. time to treatment was present such that earlier 
aieatment conferred a relative benefit. for t-PA compared with 
that for streptakinase (7). Further, the final report had initially 
indicated no difference between t-PA and streptakinase fdr 
patients- treated r4 h, the, time when mtis! ;patients in. the 
United States presen; for treatkent (7). However, :the 
GUSTG-1 investigators subsequently published two separate 
corretiions cvf these data (19,2D). The most recent corrected 
data now show greater apparent bc fLefit of accelerated t-PA for 
the later-treated patients but I&s apparent benefit of acceler- 
ated t-PA for earlier-treateA patients. These coirected data, 
-therefore, raise questions about ti:,: interrelations of advanced 
patency (21) and’ lower mbrtality for =arIier-treated patients 
who re&ive t-PA. 5 .3 
Finally, the IWO streptok&& arms were combined in many 
important GUSTO-1 anaIyse5, raising qutstio:ls that wouid be 
answered by presentation of aI data mleparstely f6r p’&zzts 
assigned to the GiSSI-2 and ISIS:3 reference arm of streptoki- 
nase with delayed stibcutaneous heparin. 
.‘_ 
‘. 
T&al&y of Evi$ence: !XSS&2, 
PSIS-3, and GUSTO-1 
The GUSTO-1 restilts make an im@rtant cdntribution to 
t5e totqlity of evidence;Which includes 5ISSI-2 and ISIS-3 (1). 
In this regard, it is particularly informative to compare. mor- 
t$ity rat& .tif patients : treated kakly .wrtb ac+ myocardial> 
infa&on before %l after GISSM9 ISIS:3 qd .&ST@1; 
Before these triah, ISIS;2 showed that patients with myocar- 
dial infarction presenting 26 h after onset of symptoms 
experienced a mortality rate of 132 per 1,000 (22), With the .UF~ 
of asgrin, ,this was decreased by 23% to--102 per 1,000, a. 
reduction timpanied by the ve$desirabIe avoidance of two 
diiabling s&k+ (22). The use of streptokin& reduced mor- 
tity rat& anoe&C30% t’J -72 per l,DOD,,wi~$h&avoidan& Of. 
one, additional ,di+bling stroke. Ewe +cept the GUSTO-l 
result,& face value, pat&n&in the,acc$erated t-PA arm had a 
M%,lo&r mqtiality r&e thti those assign&i to streptokinase 
witIi delay&d &.bcutaneoti heparin (7). Thus, the use ,uf 
: a$ceIerated &% instead &.rep&@e might be +qected:to 
ieduce the mortaiity rate to 63 per LODO, but &h about two 
extra disabIing stroke& Therefore, patie,nts assigned ‘+a rec&ve 
;acceIet’ated t-PA in GUSTO-1 had, at rnpa, a smaII but sign@- 
cant benefit compared. with the .very large and ‘h&I@ sigM%xut. 
benefits achieved Erorn aspi& aed thrombotjltic theram with 
arry apt-. : 
.. Such a cunclusiou Ian. abo be I-&ached from,an &ervieti CT 
meta-analysis of all- three trials, which indicates a small. but 
no?significant reduction in mo&Iity from t-PA ,tid larger and 
signifi-t stroke anQ’cereb&I Qetiorrhage excws$S;‘from t-PA; 
How&er, such a statistical o$xvie*ti muit be’inteiebreted wilh 
caution becau&GWSTO-1 used an ac&erated t-PA-regimen, : 
and, ISIS3. randomized patients’ up to 24’,h. after symptoms 
onszt. ; 
j 
Futwe C@allenges in Thmmbolytic Therapy 
for Acde Myo;cardia% Lrrfartiion 
In summary, we fully concur with the GUSTO investigators 
that “interpretation of clinical trial results often leaves rmrn 
for diIFerent perspectives” rind that once “all the &ues are Iaid 
out in plain view . . . ultimately, better science and improved 
patient care are the end results” (14). Regardless of the 
answers to any remaining. questions suteunding GUSTO-J, 
the folIowing observations, supported by the totahty 6f the 
evidence, represent the essential chaIIenge for clinicians seek- 
ing the optimal thrombolytic iegimen for their patients with 
acbia myocardial infarction. : 
Thrombolytic therapy and aspirin consistently save I&es in 
acute nrjroCar&al infpmion. Unfortunateiy;D&: therapies 
remain underutilhed in themUnited States: as few as 4~~ of 
patients with myocardial infarction receive thrombolysis 
(U), and 72% receive aspirin in the United States (24) 
compared with =mparabIe Figures of as hi@ as 68Yd and 
84%, res?ectiveIy, in the United Kingdom (25). Thus, the 
major ciinical -challengb in the United States is to exp3nd 
the utilization of thrombolytic agents to a11 patients presenr- 
ing -within 12 h and aspirin.to aII patients presenting within 
24 h, a strategy that WuId avoid 10,000 premature .deaahs in 
th&‘Ur@#States e&&yea! (26). 
F&her large benefits may be derived from wider &z&on 
6f throinbolytic therapy aniong those 265 years tild as well 
as,patienk presenting with either ,ST se&-em elevation or 
+ndle,branch block on ac.lr@sio~ eIectiocardio@phy (16). 
In the irnited St.&s the average time from onset of symptoms 
to,hospitaI presentatibn is -4.8 hi, ztid for presentatiur! for 
thromboIysis 1.5 h. ‘.These 1 *lays ‘&@d be reduced to 1.8 
and $5 h,. reqxtively (27). Thus, tb achieve earuliet admin- 
istiation’of, th+mboIyCc thera@y would require a reduc$&n 
of time io Ijresentation as weil as door-t&needle ,- time. 
Proven measures : to red& in-h&piiat delay. to f&iit.at< 
prompt &ninistrat/on of~,$roinboIyti~ theraI$ should be 
instituted. A pri&y .of: future re@rch, should be to seek 
eff&tiv$ ways to r~tice the iaqest combonent of delay, that 
%fore hdspiti. p~&entati&. ‘. : ’ ‘. .’ 
Thi, the smdI diIYe&esi in e&&y; s&t$ and ease df 
administration of differetit thr&mboIytic agents are fai ; 
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wider ut&ation an@ earlier administration of& of the 
available agents. 
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